Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926432 | 0.78 | MEN1 (0.60) | KDM4CMEN1KMT2AEGLN1 | |
| SCHEMBL522860 | 0.75 | EGLN2 (0.53) | EGLN2EGLN1 | |
| SCHEMBL522859 | 0.75 | EGLN2 (0.53) | EGLN2EGLN1 | |
| SCHEMBL522777 | 0.71 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL964665 | 0.71 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL30402374 | 0.71 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL522778 | 0.71 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL3991728 | 0.70 | KMT2A (0.50) | MEN1KMT2ASCN9A | |
| SCHEMBL523001 | 0.70 | EGLN2 (0.70) | EGLN2EGLN1 | |
| SCHEMBL523000 | 0.70 | EGLN2 (0.70) | EGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101394843-A | Improved anemia treatment using HIF alpha stabilizers | FIBROGEN INC (US) | 2009-03-25 | — | — | CN | disclosed |